Pardes Biosciences, Inc. (PRDS): Price and Financial Metrics


Pardes Biosciences, Inc. (PRDS): $5.78

0.16 (+2.85%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add PRDS to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

PRDS Stock Price Chart Interactive Chart >

Price chart for PRDS

PRDS Price/Volume Stats

Current price $5.78 52-week high $17.76
Prev. close $5.62 52-week low $4.89
Day low $5.63 Volume 83,900
Day high $5.82 Avg. volume 316,829
50-day MA $7.07 Dividend yield N/A
200-day MA $9.84 Market Cap 360.55M

Pardes Biosciences, Inc. (PRDS) Company Bio


Pardes Biosciences, Inc., a pre-clinical stage biotechnology company, engages in developing oral direct acting antivirals. Its antivirals target viral main cysteine protease, an essential viral protein required for coronaviruses to replicate. Pardes Biosciences, Inc. was incorporated in 2020 and is based in Carlsbad, California.


PRDS Latest News Stream


Event/Time News Detail
Loading, please wait...

PRDS Latest Social Stream


Loading social stream, please wait...

View Full PRDS Social Stream

Latest PRDS News From Around the Web

Below are the latest news stories about Pardes Biosciences Inc that investors may wish to consider to help them evaluate PRDS as an investment opportunity.

Pardes Biosciences (PRDS) presents at CROI 2022 - Slideshow

The following slide deck was published by Pardes Biosciences, Inc. in conjunction with this event....

SA Transcripts on Seeking Alpha | February 17, 2022

Pardes Biosciences Presents Interim Clinical Data from Ongoing PBI-0451 Phase 1 Trial Supporting the Potential of PBI-0451 as a Stand-Alone Oral Regimen for COVID-19 at Conference on Retroviruses and Opportunistic Infections 2022

PBI-0451 administered twice-daily as a stand-alone agent achieves and maintains PK exposures anticipated to provide potent antiviral activity against SARS-CoV-2 PBI-0451 has been generally well-tolerated and has shown good oral bioavailability Company to host conference call and webcast Tuesday, February 15, 2022 at 3:00 p.m. PT / 6:00 p.m. ET CARLSBAD, Calif., Feb. 14, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company developing PBI-045

Yahoo | February 14, 2022

Pardes Biosciences to Host Virtual Investor Event

Company to host conference call and webcast at 3 p.m. PT on Tuesday, February 15, 2022CARLSBAD, Calif., Feb. 09, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential novel direct-acting, oral antiviral drug candidate for the treatment and prevention of SARS-CoV-2 infections and associated diseases (i.e. COVID-19), today announced that a virtual investor event will be hosted by the company’s management team

Yahoo | February 9, 2022

Pardes Biosciences to Present Clinical Data from Ongoing PBI-0451 Phase 1 Trial at Conference On Retroviruses And Opportunistic Infections 2022

CARLSBAD, Calif., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential novel direct-acting, oral antiviral drug candidate for the treatment and prevention of SARS-CoV-2 infections and associated diseases (i.e. COVID-19), today announced that a late-breaker poster presentation sharing clinical data from the ongoing PBI-0451 Phase 1 trial will be presented at the 29th Conference On Retroviruses And

Yahoo | February 8, 2022

Monashee Investment Management LLC Buys Vanguard Total Stock Market ETF, Hyperfine Inc, Agree ...

Investment company Monashee Investment Management LLC (Current Portfolio) buys Vanguard Total Stock Market ETF, Hyperfine Inc, Agree Realty Corp, Pardes Biosciences Inc, DocGo Inc, sells Maravai LifeSciences Holdings Inc, SomaLogic Inc, MoneyLion Inc, RBC Bearings Inc, BioAtla Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Monashee Investment Management LLC.

Yahoo | February 7, 2022

Read More 'PRDS' Stories Here

PRDS Price Returns

1-mo -22.21%
3-mo -13.73%
6-mo -60.79%
1-year -42.14%
3-year N/A
5-year N/A
YTD -64.69%
2021 N/A
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.3714 seconds.